Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer

W. A. Verborg, L. R. Campbell, M.S. Highley, E.M. Rankin

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)


    The optimal treatment of progressive ovarian cancer after first-line platinum-based therapy remains a challenge. We collected prospectively data on patients with relapsed or progressive ovarian cancer treated with weekly cisplatin and oral etoposide in our institution to evaluate the feasibility, efficacy, and toxicity of this regimen. Patients (n = 34) had stage IIIC/IV ovarian cancer, which was recurrent or progressive following previous treatment with carboplatin and a taxane. Cisplatin (50 mg/m2) was given days 1, 8, 15, 29, 36, and 43, with oral etoposide (50 mg daily) on days 1–15 and 29–43. Responders and those with stable disease then received oral etoposide (50 mg daily for 21 days of a 28-day cycle) until disease progression. The overall CA125 response rate was 88%. The overall radiological response rate was 57%: 78% in the platinum-sensitive group, 50% in the intermediate-sensitive group, and 46% in the platinum-resistant group. Treatment was well tolerated. Median survival in the overall group was 14 months: in the platinum-sensitive group 16.5 months, in the intermediate-sensitive group 11 months, and 10.5 months in the platinum-resistant group. We conclude that weekly cisplatin/etoposide, followed by maintenance oral etoposide, is an active and well-tolerated regimen in relapsed or progressive ovarian cancer, even in platinum-resistant patients.
    Original languageEnglish
    Pages (from-to)228-234
    Number of pages7
    JournalInternational Journal of Gynecological Cancer
    Issue number2
    Publication statusPublished - 2008


    • Cisplatin
    • Etoposide
    • Ovarian cancer
    • Relapse


    Dive into the research topics of 'Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer'. Together they form a unique fingerprint.

    Cite this